Assessment of oritavancin serum protein binding across species.
about
Oritavancin: a long-acting antibacterial lipoglycopeptide.Comparative Pharmacodynamics of Single-Dose Oritavancin and Daily High-Dose Daptomycin Regimens against Vancomycin-resistant Enterococcus faecium Isolates in an In Vitro PK/PD Model of Infection.Oritavancin Pharmacokinetics and Bone Penetration in Rabbits.Pharmacodynamics of a simulated single 1,200-milligram dose of oritavancin in an in vitro pharmacokinetic/pharmacodynamic model of methicillin-resistant staphylococcus aureus infection.Developments in Glycopeptide Antibiotics.In vivo activity of oritavancin in animal infection models and rationale for a new dosing regimen in humans.
P2860
Assessment of oritavancin serum protein binding across species.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh
2010年學術文章
@zh-hant
name
Assessment of oritavancin serum protein binding across species.
@en
Assessment of oritavancin serum protein binding across species.
@nl
type
label
Assessment of oritavancin serum protein binding across species.
@en
Assessment of oritavancin serum protein binding across species.
@nl
prefLabel
Assessment of oritavancin serum protein binding across species.
@en
Assessment of oritavancin serum protein binding across species.
@nl
P2093
P2860
P356
P1476
Assessment of oritavancin serum protein binding across species.
@en
P2093
Adam Belley
Francis F Arhin
Geoffrey McKay
Gregory Moeck
Ingrid Sarmiento
Sylvain Beaulieu
Thomas R Parr
P2860
P304
P356
10.1128/AAC.00271-10
P407
P577
2010-05-24T00:00:00Z